Titan Medical Inc (TMDIF)

[66Mustang]

As a reminder, with our desire for news, I will paste in the milestones for Q3 and Q4 of 2017 (as shown in the June 27 Final Short Form Prospectus). Also as a reminder, next week we are half way through Q3. Within about 7 weeks from now, we SHOULD be hearing something about the progress on these Q3 tasks. These are important milestones for this phase of the program, but I still expect the market to respond to any of these positive announcements with the typical indifference we have seen. Barring announcements pertaining to securing of substantial funding or major partnership/buyout (something at least two orders of magnitude beyond their latest $2M partnership), I think patience will continue to be required.

Q3:
Complete and verify system design
architecture, including performance testing in
laboratory environment and design of
surgeon simulation training modules
- Implement design changes and retest
system and subsystems
- Update Design History File and
documentation for relevant modules of
Company Quality Management
Systems (“QMS”)
- Complete initial requirements and
architecture for surgeon simulation
software and training program design,
as required in preparation for FDA
submittal

Q4:
Verify system performance in pre-clinical
(live animal labs, swine), while establishing
clear regulatory pathways for US and Europe
- Complete and report on pre-clinical
live animal (swine) studies at strategic
facilities in US and Europe
- Confirm FDA and CE Mark pathways
in coordination with regulatory
authorities